Tarsus Pharmaceuticals, Inc. TARS Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — total revenues?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — total revenues of $162.05M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — total revenues changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — total revenues increased by 106.9% year-over-year, from $78.34M to $162.05M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — total revenues?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — total revenues has grown at a 159.5% compound annual growth rate (CAGR), from $25.82M to $451.36M.
- What does business segments — total revenues mean?
- Represents the total gross inflow of economic benefits arising from the ordinary operating activities of the business segment. This metric reflects the market demand and commercial success of the company's therapeutic products within its primary reportable segment.